Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment

BACKGROUND: Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardized, and clinical trials investigate treatment effects at population level. Genomics-driven oncology for stratified treatments allow clinical decision making in only a small minority of screened patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Skaga, Erlend, Kulesskiy, Evgeny, Brynjulvsen, Marit, Sandberg, Cecilie J., Potdar, Swapnil, Langmoen, Iver A., Laakso, Aki, Gaál-Paavola, Emília, Perola, Markus, Wennerberg, Krister, Vik-Mo, Einar O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937360/
https://www.ncbi.nlm.nih.gov/pubmed/31889236
http://dx.doi.org/10.1186/s40169-019-0253-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937360/
https://www.ncbi.nlm.nih.gov/pubmed/31889236
http://dx.doi.org/10.1186/s40169-019-0253-6

Ejemplares similares